These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1416573)

  • 41. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance.
    Bogazzi F; Lombardi M; Strata E; Aquaro G; Lombardi M; Urbani C; Di Bello V; Cosci C; Sardella C; Talini E; Martino E
    J Endocrinol Invest; 2010 Feb; 33(2):103-8. PubMed ID: 20348836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effective long-term treatment of acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Sandler LM; Burrin JM; Williams G; Joplin GF; Carr DH; Bloom SR
    Clin Endocrinol (Oxf); 1987 Jan; 26(1):85-95. PubMed ID: 2879656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.
    Garcia MB; Koppeschaar HP; Lips CJ; Thijssen JH; Krenning EP
    J Endocrinol Invest; 1994 Jan; 17(1):59-65. PubMed ID: 7911814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
    Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
    J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acromegalic cardiopathy improves after treatment with increasing doses of octreotide.
    Pereira JL; Rodriguez-Puras MJ; Leal-Cerro A; Martinez A; Garcia-Luna PP; Gavilan I; Pumar A; Astorga R
    J Endocrinol Invest; 1991 Jan; 14(1):17-23. PubMed ID: 2045621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
    Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy.
    Tachibana H; Yamaguchi H; Abe S; Sato T; Inoue S; Abe S; Yamaki M; Kubota I
    Jpn Heart J; 2003 Nov; 44(6):1027-31. PubMed ID: 14711197
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
    Fredstorp L; Werner S
    J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: studies in acromegaly and growth hormone deficiency.
    Hoogenberg K; Sluiter WJ; Dullaart RP
    Acta Endocrinol (Copenh); 1993 Aug; 129(2):151-7. PubMed ID: 8372600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects.
    Fredstorp L; Harris A; Haas G; Werner S
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1189-94. PubMed ID: 2229278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
    Lamberts SW; Uitterlinden P; del Pozo E
    J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of efficacy of octreotide therapy in patients with acromegaly.
    Colao A; Ferone D; Lastoria S; Marzullo P; Cerbone G; Di Sarno A; Longobardi S; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2356-62. PubMed ID: 8964877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients.
    Fatti LM; Scacchi M; Lavezzi E; Pecori Giraldi F; De Martin M; Toja P; Michailidis G; Stramba-Badiale M; Cavagnini F
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):626-30. PubMed ID: 17054464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide.
    Avagnina P; Martini M; Terzolo M; Sansoé G; Peretti P; Tinivella M; Pia A; Molino G; Angeli A
    Metabolism; 1996 Jan; 45(1):109-13. PubMed ID: 8544766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.